2 years ago

Maxiom Therapeutics Secures $16 Million Series A Funding for KnotBody Platform

  • Maxiom Therapeutics, a UK-based biotech company developing biologic medicines for ion channels and G-protein-coupled receptors (GPCRs), secured $16 million in Series A funding led by LifeArc Ventures, Monograph Capital, and BGF

  • This investment will fuel the development of antibody drugs against ion channels and GPCRs using Maxiom's proprietary KnotBody platform, a technology that combines the functional activity of 'knottins' with the desirable drug properties of antibodies

  • The funding will enable Maxion to advance its R&D efforts and develop potential first-in-class and best-in-class therapeutics for a range of diseases.

      • ProblemHealthcare

      "Many diseases, including autoimmune conditions and chronic pain, are poorly treated because existing medications are ineffective or have severe side effects. Existing drugs target ion channels and G-protein-coupled receptors (GPCRs), but they often lack specificity and have short durations of action. "

      Solution

      "Maxion Therapeutics is developing a new class of biologic medicines that target ion channels and GPCRs with high specificity and long-lasting effects. The company's proprietary KnotBody platform uses naturally occurring cysteine-rich miniproteins called “knottins” to modulate ion channels and GPCRs. These knottins are fused onto the surface of antibodies, creating “KnotBodies” that combine the functional activity of knottins with the excellent drug properties of antibodies. "

      Covered on